- Home
- WRLD vs ATXS Comparison
WRLD vs ATXS Comparison
Compare WRLD & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- ATXS
- Stock Information
- Founded
- WRLD 1962
- ATXS 2008
- Country
- WRLD United States
- ATXS United States
- Employees
- WRLD N/A
- ATXS N/A
- Industry
- WRLD Finance: Consumer Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- ATXS Health Care
- Exchange
- WRLD Nasdaq
- ATXS Nasdaq
- Market Cap
- WRLD 690.7M
- ATXS 669.8M
- IPO Year
- WRLD 1991
- ATXS 2015
- Fundamental
- Price
- WRLD $117.57
- ATXS $9.34
- Analyst Decision
- WRLD
- ATXS Strong Buy
- Analyst Count
- WRLD 0
- ATXS 5
- Target Price
- WRLD N/A
- ATXS $25.60
- AVG Volume (30 Days)
- WRLD 20.0K
- ATXS 232.2K
- Earning Date
- WRLD 10-25-2024
- ATXS 11-13-2024
- Dividend Yield
- WRLD N/A
- ATXS N/A
- EPS Growth
- WRLD 57.43
- ATXS N/A
- EPS
- WRLD 14.74
- ATXS N/A
- Revenue
- WRLD $557,739,360.00
- ATXS N/A
- Revenue This Year
- WRLD N/A
- ATXS N/A
- Revenue Next Year
- WRLD $0.78
- ATXS N/A
- P/E Ratio
- WRLD $7.97
- ATXS N/A
- Revenue Growth
- WRLD N/A
- ATXS N/A
- 52 Week Low
- WRLD $101.85
- ATXS $4.43
- 52 Week High
- WRLD $149.31
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- WRLD 49.53
- ATXS 34.13
- Support Level
- WRLD $115.19
- ATXS $8.61
- Resistance Level
- WRLD $118.66
- ATXS $9.79
- Average True Range (ATR)
- WRLD 2.89
- ATXS 0.77
- MACD
- WRLD -0.45
- ATXS -0.23
- Stochastic Oscillator
- WRLD 34.48
- ATXS 18.91
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.